A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Incyte Corporation

Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Age ≥18 years. * ECOG performance status of 0 or 1. * Histologically confirmed: * Clear cell renal cell carcinoma (ccRCC). * Diffuse large B-cell lymphoma (DLBCL, NOS). * High-grade B-cell lymphoma (HGBCL). * Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL). * Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement). * Disease progression, relapse, or refractory to prior therapy: * ccRCC: ≥1 prior line incl. ICI + TKI. * DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage. * PTCL/CTCL: ≥1 prior systemic…

Interventions

Drug
INCA036873
Intravenously (IV)

Locations (22)

City of Hope Medical Center
Duarte, California
University of California San Diego Medical Center, Moores Cancer Center
La Jolla, California
University of Michigan
Ann Arbor, Michigan
The University of Nebraska Medical Center
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center
New York, New York
Scri Oncology Partners
Nashville, Tennessee